Loading organizations...
Principia Biopharma was a clinical-stage biopharmaceutical company focused on developing transformative oral small molecule therapies for patients with significant unmet medical needs in immune-mediated diseases and oncology. Leveraging its proprietary Tailored Covalency® platform, the company designed reversible and irreversible covalent inhibitors engineered to achieve the potency and selectivity often associated with injectable biologics, while offering the convenience of an oral pill. Their lead product candidate, rilzabrutinib, was a reversible covalent BTK inhibitor targeting conditions like pemphigus vulgaris, immune thrombocytopenia, and IgG4-related diseases.
The company was founded in 2008 by Richard A. Miller and Jack Taunton, emerging from an insight to create highly specific and potent covalent compounds for treating complex autoimmune disorders and cancer. Dr. Taunton, a notable researcher from UCSF, brought a strong scientific foundation in protein kinase inhibitor development, which directly informed Principia's unique chemical platform and therapeutic approach to drug discovery.
Principia's therapies were intended for individuals suffering from chronic and debilitating autoimmune and neuro-inflammatory conditions, where existing treatments might be insufficient or burdensome. The company's vision centered on expanding the utility of oral medications by developing drug candidates that combine the efficacy of biologics with the accessibility of small molecules, thereby improving patient outcomes and quality of life for a broad range of challenging diseases.
Principia Biopharma has raised $78.0M across 3 funding rounds.
Principia Biopharma has raised $78.0M in total across 3 funding rounds.
Principia Biopharma has raised $78.0M across 3 funding rounds. Most recently, it raised $15.0M Series B in August 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2015 | $15M Series B | — | Atlas Venture, Frazier Healthcare Partners, Highbury Group, Johnson & Johnson Innovation, Kurma Partners, Morgenthaler Ventures, OrbiMed, Samsara BioCapital, SR ONE | Announced |
| Apr 1, 2014 | $50M Series B | Srinivas Akkaraju | Atlas Venture, Frazier Healthcare Partners, Highbury Group, Johnson & Johnson Innovation, Kurma Partners, Morgenthaler Ventures, OrbiMed, Samsara BioCapital, SR ONE, Mission BAY Capital, Morgenthaler Ventures, NEW Leaf Venture Partners | Announced |
| Oct 1, 2012 | $13M Series A | — | Atlas Venture, Frazier Healthcare Partners, Highbury Group, Johnson & Johnson Innovation, Kurma Partners, Morgenthaler Ventures, OrbiMed, Samsara BioCapital, SR ONE, Mission BAY Capital, Morgenthaler Ventures, NEW Leaf Venture Partners | Announced |
Principia Biopharma has raised $78.0M in total across 3 funding rounds.
Principia Biopharma's investors include Atlas Venture, Frazier Healthcare Partners, Highbury Group, Johnson & Johnson Innovation, Kurma Partners, Morgenthaler Ventures, OrbiMed, Samsara BioCapital, SR One, Srinivas Akkaraju, Mission Bay Capital, New Leaf Venture Partners.
Principia Biopharma is a clinical‑stage biopharmaceutical company (acquired by Sanofi in 2020) that developed a proprietary “Tailored Covalency” platform for designing reversible and irreversible covalent small‑molecule inhibitors, with a focus on Bruton's tyrosine kinase (BTK) and other targets in autoimmune, allergic and oncology indications.[5][4]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Pharma Landscape
Quick Take & Future Outlook
Quick reminder: Principia’s defining claim is its engineered reversible covalent chemistry and a BTK‑centric pipeline that proved compelling enough to drive partnerships, an IPO, and a strategic acquisition by Sanofi in 2020.[2][3][4]